BRPI0915888E2 - polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso - Google Patents
polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu usoInfo
- Publication number
- BRPI0915888E2 BRPI0915888E2 BRC10915888A BRPI0915888A BRPI0915888E2 BR PI0915888 E2 BRPI0915888 E2 BR PI0915888E2 BR C10915888 A BRC10915888 A BR C10915888A BR PI0915888 A BRPI0915888 A BR PI0915888A BR PI0915888 E2 BRPI0915888 E2 BR PI0915888E2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor
- polypeptide
- acid sequence
- nucleic acid
- sequence encoding
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000007523 nucleic acids Chemical group 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 108010073466 Bombesin Receptors Proteins 0.000 abstract 1
- 102100030851 Cortistatin Human genes 0.000 abstract 1
- 229930185483 Cortistatin Natural products 0.000 abstract 1
- 108010016122 Ghrelin Receptors Proteins 0.000 abstract 1
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 abstract 1
- 101710198286 Growth hormone-releasing hormone receptor Proteins 0.000 abstract 1
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 abstract 1
- 102100034845 KiSS-1 receptor Human genes 0.000 abstract 1
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 abstract 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 abstract 1
- 102000056271 Prolactin-releasing peptide receptors Human genes 0.000 abstract 1
- 108700024163 Prolactin-releasing peptide receptors Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 101150056450 UTS2R gene Proteins 0.000 abstract 1
- 108010005430 cortistatin Proteins 0.000 abstract 1
- 108091008039 hormone receptors Proteins 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 abstract 1
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 1
- 231100000065 noncytotoxic Toxicity 0.000 abstract 1
- 230000002020 noncytotoxic effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0810782.3A GB0810782D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of cancers |
| GB0810785A GB0810785D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of neuroendocrine diseases |
| GB0810785.6 | 2008-06-12 | ||
| GB0810782.3 | 2008-06-12 | ||
| GB0820884.5 | 2008-11-14 | ||
| GB0820884A GB0820884D0 (en) | 2008-11-14 | 2008-11-14 | Suppression of neuroendocrine diseases |
| GB0820965.2 | 2008-11-17 | ||
| GB0820965A GB0820965D0 (en) | 2008-11-17 | 2008-11-17 | Suppression of cancers |
| PCT/GB2009/050665 WO2009150469A2 (en) | 2008-06-12 | 2009-06-11 | Suppression of neuroendocrine diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0915888A2 BRPI0915888A2 (pt) | 2020-06-30 |
| BRPI0915888E2 true BRPI0915888E2 (pt) | 2020-09-01 |
Family
ID=41417177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRC10915888A BRPI0915888E2 (pt) | 2008-06-12 | 2009-06-11 | polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110171191A1 (enExample) |
| EP (3) | EP2719392B1 (enExample) |
| JP (2) | JP5728380B2 (enExample) |
| KR (1) | KR101642363B1 (enExample) |
| CN (2) | CN104328100B (enExample) |
| AU (1) | AU2009259033B2 (enExample) |
| BR (1) | BRPI0915888E2 (enExample) |
| CA (1) | CA2727082C (enExample) |
| ES (2) | ES2614990T3 (enExample) |
| IL (1) | IL209855A (enExample) |
| WO (1) | WO2009150469A2 (enExample) |
| ZA (1) | ZA201008536B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| GB0803068D0 (en) | 2008-02-20 | 2008-03-26 | Health Prot Agency | Cross-linked biological indicator |
| US10466245B2 (en) | 2008-02-20 | 2019-11-05 | The Secretary Of State For Health | Covalently linked thermostable kinase for decontamination process validation |
| CA2727082C (en) * | 2008-06-12 | 2019-02-26 | Syntaxin Limited | Fusion proteins for use in suppression of acromegaly |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| MX355543B (es) | 2010-08-13 | 2018-04-20 | Aileron Therapeutics Inc Star | Macrociclos peptidomiméticos. |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
| SG11201404648PA (en) | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| EP3194618B1 (en) | 2014-09-15 | 2021-04-21 | Clifton Life Sciences LLC | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm |
| SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| US20170326166A1 (en) * | 2014-10-17 | 2017-11-16 | University Of Virginia Patent Foundation | Compositions and methods for treating pituitary tumors |
| KR20170129879A (ko) | 2015-03-20 | 2017-11-27 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| US20210277071A1 (en) | 2016-09-29 | 2021-09-09 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3375871A1 (en) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Selective cell death-inducing enzyme system |
| JOP20190276A1 (ar) * | 2017-05-31 | 2019-11-27 | Napo Pharmaceuticals Inc | طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة |
| BR112020006827A2 (pt) | 2018-01-29 | 2020-10-06 | Ipsen Biopharm Limited | neurotoxinas botulínicas clivando snare não neuronal |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| CN110801512B (zh) * | 2019-11-15 | 2023-07-18 | 中国水产科学研究院黑龙江水产研究所 | 一种用于促进哲罗鲑性腺成熟的多肽及其应用 |
| CN111388651B (zh) * | 2020-05-09 | 2022-05-03 | 山东大学齐鲁医院 | Cst-14在制备骨质疏松症治疗药物中的应用 |
| CN113257370B (zh) * | 2021-05-12 | 2022-09-02 | 中国医学科学院北京协和医院 | 基于临床病理基本信息和vista检测的pnet复发风险预测模型 |
| WO2025155896A1 (en) * | 2024-01-19 | 2025-07-24 | Sling Therapeutics, Inc. | Use of inhibitors of insulin-like growth factor receptor-1 for growth hormone igf-secreting neoplasias |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
| US4133782A (en) | 1976-06-07 | 1979-01-09 | The Salk Institute For Biological Studies | Somatostatin analogs with dissociated biological activities |
| US4190575A (en) | 1977-12-27 | 1980-02-26 | American Home Products Corporation | Polypeptides related to somatostatin |
| DE2860734D1 (en) | 1977-06-08 | 1981-09-03 | Merck & Co Inc | Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them |
| US4211693A (en) | 1977-09-20 | 1980-07-08 | The Salk Institute For Biological Studies | Peptides with para-substituted phenylalanine |
| LU78191A1 (de) | 1977-09-28 | 1979-05-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen cyclopeptiden |
| JPS5819669B2 (ja) | 1978-10-28 | 1983-04-19 | 白井松新薬株式会社 | 新規生理活性ペプチド化合物及びその製造法 |
| US4190648A (en) | 1979-03-13 | 1980-02-26 | Merck & Co., Inc. | Peptides having somatostatin activity |
| US4316890A (en) | 1979-03-16 | 1982-02-23 | Ciba-Geigy Corporation | Peptides and processes for the manufacture thereof |
| US4328214A (en) | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4369179A (en) | 1979-12-14 | 1983-01-18 | Ciba-Geigy Corporation | Acylpeptides |
| US4282143A (en) | 1980-06-13 | 1981-08-04 | American Home Products Corporation | Octapeptides lowering growth hormone |
| US4360516A (en) | 1981-04-13 | 1982-11-23 | Merck & Co., Inc. | Modified D-retro cyclic hexapeptide somatostatin analogs |
| DE3264693D1 (en) | 1981-12-24 | 1985-08-14 | Ciba Geigy Ag | Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use |
| FR2522655B1 (fr) | 1982-03-05 | 1987-03-06 | Sanofi Sa | Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant |
| US4522813A (en) | 1983-10-27 | 1985-06-11 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4659693A (en) | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
| US4632979A (en) | 1984-06-18 | 1986-12-30 | Tulane Educational Fund | Therapeutic LHRH analogs |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
| US4725577A (en) | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
| US4585755A (en) | 1985-04-29 | 1986-04-29 | Merck & Co., Inc. | Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents |
| US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4803261A (en) | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
| JP2795449B2 (ja) | 1987-09-24 | 1998-09-10 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 治療用ペプチド |
| US5084555A (en) | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
| AU632468B2 (en) | 1988-02-01 | 1993-01-07 | Upjohn Company, The | Renin inhibiting peptides with polar end groups |
| NO893088L (no) | 1988-08-18 | 1990-02-19 | Syntex Inc | Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68928667T2 (de) | 1988-10-14 | 1998-10-01 | Univ Tulane | Peptide als arzneimittel |
| US5171835A (en) | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
| WO1990012811A1 (en) | 1989-04-26 | 1990-11-01 | The Administrators Of The Tulane Educational Fund | Linear somatostatin analogs |
| JP2925321B2 (ja) | 1989-12-08 | 1999-07-28 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | ６位にスレオニンを有するソマトスタチン類縁体オクタペプチド |
| ATE127476T1 (de) | 1990-04-06 | 1995-09-15 | Univ Tulane | Lhrh-analoge. |
| EP0527914A4 (en) | 1990-05-04 | 1993-08-11 | The Administrators Of The Tulane University Educational Fund | Novel synthetic grf analogs |
| EP0531342A1 (en) | 1990-05-09 | 1993-03-17 | The Administrators Of The Tulane Educational Fund | Cyclized and linear therapeutic peptides |
| IT1240643B (it) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| HU207104B (en) | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
| US6083915A (en) | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
| US5240561A (en) | 1992-02-10 | 1993-08-31 | Industrial Progress, Inc. | Acid-to-alkaline papermaking process |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| US5656727A (en) | 1992-09-15 | 1997-08-12 | The Administrators Of The Tulane Educational Fund | Antagonists of LHRH |
| AU5727194A (en) | 1992-11-13 | 1994-06-08 | The Administrators Of The Tulane Eductional Fund | Ghrh agonists |
| AU5668894A (en) | 1992-11-13 | 1994-06-08 | The Administrators Of The Tulane Eductional Fund | Ghrh agonists |
| GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| WO1995004752A1 (en) | 1993-08-09 | 1995-02-16 | Biomeasure, Inc. | Therapeutic peptide derivatives |
| US5550212A (en) | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
| AUPM985694A0 (en) | 1994-12-02 | 1995-01-05 | Farmer, Mostyn | Golf training aid |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| DE69504634T2 (de) | 1995-03-13 | 1999-03-25 | Biomeasure, Inc., Milford, Mass. | Bombesin-Analogen |
| EP0820296A4 (en) | 1995-04-14 | 1999-06-30 | Univ Tulane | ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| US5942489A (en) | 1996-05-03 | 1999-08-24 | The Administrators Of The Tulane Educational Fund | HGH-RH(1-29)NH2 analogues having antagonistic activity |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| WO1998008528A1 (en) | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| US5968903A (en) | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
| AU755513B2 (en) | 1998-05-13 | 2002-12-12 | Merz Pharma Gmbh & Co. Kgaa | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| DE69934337T2 (de) | 1998-07-22 | 2007-05-24 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung |
| JP2002521456A (ja) | 1998-07-30 | 2002-07-16 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | ソマトスタチン類似体の使用法 |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| IL146884A0 (en) | 1999-06-04 | 2002-08-14 | Sod Conseils Rech Applic | Neuromedin b and somatostatin receptor agonists |
| US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| EP1700918B1 (en) * | 1999-08-25 | 2014-01-15 | Allergan, Inc. | Activatable recombinant neurotoxins |
| US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| WO2004076634A2 (en) * | 2003-02-24 | 2004-09-10 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
| TW200517400A (en) * | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| WO2006026780A1 (en) * | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| AU2005311086B2 (en) * | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8052979B2 (en) * | 2005-03-15 | 2011-11-08 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| DE602006013481D1 (de) | 2005-09-19 | 2010-05-20 | Allergan Inc | Mit clostriedientoxin aktivierbare clostridientoxine |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| CA2658260A1 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| AU2007272517B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| CA2727082C (en) * | 2008-06-12 | 2019-02-26 | Syntaxin Limited | Fusion proteins for use in suppression of acromegaly |
| CN102083451A (zh) * | 2008-06-12 | 2011-06-01 | 赛恩泰新公司 | 癌症的抑制 |
| US10057187B1 (en) | 2015-05-27 | 2018-08-21 | Amazon Technologies, Inc. | Dynamic resource creation to connect client resources in a distributed system |
-
2009
- 2009-06-11 CA CA2727082A patent/CA2727082C/en not_active Expired - Fee Related
- 2009-06-11 EP EP13179177.4A patent/EP2719392B1/en active Active
- 2009-06-11 WO PCT/GB2009/050665 patent/WO2009150469A2/en not_active Ceased
- 2009-06-11 CN CN201410295607.7A patent/CN104328100B/zh not_active Expired - Fee Related
- 2009-06-11 ES ES09762018.1T patent/ES2614990T3/es active Active
- 2009-06-11 KR KR1020117000251A patent/KR101642363B1/ko not_active Expired - Fee Related
- 2009-06-11 EP EP09762018.1A patent/EP2310028B1/en active Active
- 2009-06-11 US US12/996,643 patent/US20110171191A1/en not_active Abandoned
- 2009-06-11 AU AU2009259033A patent/AU2009259033B2/en not_active Ceased
- 2009-06-11 CN CN200980130069.3A patent/CN102112145B/zh not_active Expired - Fee Related
- 2009-06-11 JP JP2011513056A patent/JP5728380B2/ja active Active
- 2009-06-11 BR BRC10915888A patent/BRPI0915888E2/pt not_active IP Right Cessation
- 2009-06-11 ES ES13179177T patent/ES2750651T3/es active Active
- 2009-06-11 EP EP19175007.4A patent/EP3590956A1/en active Pending
-
2010
- 2010-11-29 ZA ZA2010/08536A patent/ZA201008536B/en unknown
- 2010-12-08 IL IL209855A patent/IL209855A/en not_active IP Right Cessation
-
2014
- 2014-04-21 JP JP2014087047A patent/JP5891258B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102112145A (zh) | 2011-06-29 |
| EP2719392A1 (en) | 2014-04-16 |
| EP2310028A2 (en) | 2011-04-20 |
| AU2009259033B2 (en) | 2013-11-07 |
| EP2310028B1 (en) | 2016-11-16 |
| US20110171191A1 (en) | 2011-07-14 |
| EP2719392B1 (en) | 2019-07-24 |
| JP5728380B2 (ja) | 2015-06-03 |
| WO2009150469A3 (en) | 2010-07-15 |
| CN104328100A (zh) | 2015-02-04 |
| ZA201008536B (en) | 2012-05-30 |
| JP2014195454A (ja) | 2014-10-16 |
| ES2750651T3 (es) | 2020-03-26 |
| IL209855A (en) | 2013-09-30 |
| KR101642363B1 (ko) | 2016-07-25 |
| KR20110038017A (ko) | 2011-04-13 |
| CA2727082C (en) | 2019-02-26 |
| JP5891258B2 (ja) | 2016-03-22 |
| IL209855A0 (en) | 2011-02-28 |
| CN104328100B (zh) | 2019-08-23 |
| CA2727082A1 (en) | 2009-12-17 |
| EP3590956A1 (en) | 2020-01-08 |
| BRPI0915888A2 (pt) | 2020-06-30 |
| AU2009259033A1 (en) | 2009-12-17 |
| WO2009150469A2 (en) | 2009-12-17 |
| ES2614990T3 (es) | 2017-06-02 |
| CN102112145B (zh) | 2014-07-30 |
| JP2011522560A (ja) | 2011-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915888E2 (pt) | polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso | |
| WO2011005540A8 (en) | Methods and compositions using peptides and proteins with c-terminal elements | |
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| CY1118038T1 (el) | Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος | |
| BRPI0910461A8 (pt) | hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso. | |
| BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
| BRPI0316092B8 (pt) | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos | |
| CL2012000119A1 (es) | Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus. | |
| WO2006097536A3 (en) | Dimeric peptide agonists of the glp-1 receptor | |
| IL209854A (en) | Polypeptide, an amino acid sequence encoded for this polypeptide, and the use of this polypeptide for the preparation of a cancer suppressant | |
| WO2010074575A3 (en) | Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv. | |
| MX2023010178A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
| WO2008079973A9 (en) | Egfr binding peptides and uses thereof | |
| PE20070033A1 (es) | Concentrado de proteina y flujo acuoso que contiene carbohidratos solubles de agua | |
| WO2009034315A3 (en) | Vaccine | |
| BRPI0816330A2 (pt) | Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina | |
| AR100768A1 (es) | Método para disminuir la inmunogenicidad de proteínas y péptidos | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| BRPI0608309A2 (pt) | administração intranasal de agentes ativos ao sistema nervoso central | |
| NZ596501A (en) | Casb7439 constructs | |
| BRPI0607097A2 (pt) | peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada | |
| WO2011053789A3 (en) | Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| PH12014500765A1 (en) | Human notch1 decoys |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: IPSEN BIOINNOVATION LIMITED (GB) |
|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B25G | Requested change of headquarter approved |
Owner name: IPSEN BIOINNOVATION LIMITED (GB) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |